CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice (Q57955465)

5

0 references

Else Marie Agger

6

object named as

Else Marie Agger

0 references

author name string

Jon Hansen

1

0 references

Julie Lindberg-Levin

3

0 references

Claus Aagaard

Cancer Immunology, Immunotherapy

4

0 references

publication date

18 November 2011

0 references

published in

0 references

volume

61

0 references

issue

6

0 references

page(s)

893-903

0 references

cites work

Vaccine adjuvants: current state and future trends

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

The critical role of type-1 innate and acquired immunity in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Therapeutic cancer vaccines: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Type I interferon as a stimulus for cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Interleukin-10 and the interleukin-10 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Transforming growth factor-beta regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Therapeutic cancer vaccines in combination with conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6

Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1156-6